TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Cyclopharm Limited ( (AU:CYC) ).
Cyclopharm Limited reported record half-year revenue growth, driven by strong commercial traction in the USA and strategic milestones that enhance its position as a leader in functional lung imaging. The company achieved a 26% increase in revenue, with significant contributions from Technegas® sales in the USA and third-party distribution. Cyclopharm secured a U.S. patent extension, ensuring exclusivity until 2031, and filed a new IP family for Technegas® generator innovations. The company’s U.S. market momentum is supported by installations in strategic centers and contracts with major hospital groups, while clinical validation continues to expand Technegas® applications beyond pulmonary embolism. Cyclopharm is poised for accelerated growth and aims for 250-300 U.S. installations by the second half of 2026.
The most recent analyst rating on (AU:CYC) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on Cyclopharm Limited stock, see the AU:CYC Stock Forecast page.
More about Cyclopharm Limited
Cyclopharm Limited is an ASX-listed radiopharmaceutical company that serves the global medical community. The company focuses on improving patient care outcomes through its core product, Technegas®, which is used in functional lung ventilation imaging.
Average Trading Volume: 60,801
Technical Sentiment Signal: Sell
Current Market Cap: A$111.7M
For an in-depth examination of CYC stock, go to TipRanks’ Overview page.